Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

NCT00099736 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

696

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation

Interventions

DRUG: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
DRUG: FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
DRUG: MMF 2 g + full-dose Neoral (FDN) + corticosteroids

Sponsor

Novartis Pharmaceuticals